Kelsey J E
Department of Psychiatry and Behavioral Medicine, Bowman Gray School of Medicine, Winston-Salem, North Carolina, USA.
J Clin Psychopharmacol. 1996 Jun;16(3 Suppl 2):21S-26S; discussion 26S-28S. doi: 10.1097/00004714-199606002-00005.
Considerations when selecting a first-line antidepressant agent include the potential for achieving greater response with increasing dosages, thereby allowing greater flexibility in dosing. The efficacy and dose-response of venlafaxine, a novel serotonin and norepinephrine reuptake inhibitor, was evaluated in two placebo-controlled studies. Both studies demonstrated that venlafaxine was efficacious (as determined by the Hamilton Rating Scale for Depression, the Montgomery-Asberg Depression Rating Scale, and the Clinical Global Impressions scale scores), as well as safe and tolerable when administered either twice or three times daily in the treatment of outpatients who had major depression. In addition, evidence of a dose-response relationship was shown in both studies.
选择一线抗抑郁药时的考虑因素包括随着剂量增加实现更大反应的可能性，从而在给药方面具有更大的灵活性。在两项安慰剂对照研究中评估了新型5-羟色胺和去甲肾上腺素再摄取抑制剂文拉法辛的疗效和剂量反应。两项研究均表明，文拉法辛有效（由汉密尔顿抑郁评定量表、蒙哥马利-阿斯伯格抑郁评定量表和临床总体印象量表评分确定），并且在治疗患有重度抑郁症的门诊患者时，每日给药两次或三次时安全且耐受性良好。此外，两项研究均显示了剂量反应关系的证据。
